Co-Authors
This is a "connection" page, showing publications co-authored by CHAN SHEN and YA-CHEN TINA SHIH.
Connection Strength
3.835
-
Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics. 2018 08; 36(8):1005-1013.
Score: 0.657
-
Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia. Cancer. 2018 01 15; 124(2):364-373.
Score: 0.621
-
Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist. 2017 12; 22(12):1451-1462.
Score: 0.609
-
Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications. J Oncol Pract. 2017 02; 13(2):e152-e162.
Score: 0.591
-
A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb; 14(1):45-69.
Score: 0.478
-
Do Robotic Surgical Systems Improve Profit Margins? A Cross-Sectional Analysis of California Hospitals. Value Health. 2017 09; 20(8):1221-1225.
Score: 0.152
-
Use of CT and Chest Radiography for Lung Cancer Screening Before and After Publication of Screening Guidelines: Intended and Unintended Uptake. JAMA Intern Med. 2017 03 01; 177(3):439-441.
Score: 0.149
-
Estimating regimen-specific costs of chemotherapy for breast cancer: Observational cohort study. Cancer. 2016 Nov 15; 122(22):3447-3455.
Score: 0.145
-
Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. Oncologist. 2016 Mar; 21(3):308-13.
Score: 0.139
-
Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1656-65.
Score: 0.134
-
Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer. 2014 Jul 01; 120(13):2039-49.
Score: 0.122
-
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017 04; 18(4):525-534.
Score: 0.037